Novartis (NVS) Competitors

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.

Does the MarketBeat Community believe in NVS or NVO?

Novartis received 102 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. However, 61.87% of users gave Novo Nordisk A/S an outperform vote while only 60.87% of users gave Novartis an outperform vote.

Company	Underperform	Outperform
Novartis	Outperform Votes 532 60.87%	Underperform Votes 342 39.13%
Novo Nordisk A/S	Outperform Votes 430 61.87%	Underperform Votes 265 38.13%

Is NVS or NVO a better dividend stock?

Novartis pays an annual dividend of $2.51 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays an annual dividend of $1.57 per share and has a dividend yield of 2.1%. Novartis pays out 42.7% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Which has more volatility & risk, NVS or NVO?

Novartis has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Do analysts recommend NVS or NVO?

Novartis currently has a consensus price target of $123.38, suggesting a potential upside of 11.84%. Novo Nordisk A/S has a consensus price target of $145.25, suggesting a potential upside of 97.43%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	3 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Novo Nordisk A/S	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 34.81% compared to Novartis' net margin of 23.56%. Novo Nordisk A/S's return on equity of 84.68% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.56%	37.24%	15.85%
Novo Nordisk A/S	34.81%	84.68%	26.29%

Do insiders and institutionals believe in NVS or NVO?

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has higher earnings and valuation, NVS or NVO?

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$51.72B	4.36	$11.94B	$5.88	18.76
Novo Nordisk A/S	$290.40B	1.14	$14.64B	$3.29	22.36

Does the media refer more to NVS or NVO?

In the previous week, Novo Nordisk A/S had 49 more articles in the media than Novartis. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 29 mentions for Novartis. Novartis' average media sentiment score of 0.98 beat Novo Nordisk A/S's score of 0.42 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	19 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	35 Very Positive mention(s)	6 Positive mention(s)	26 Neutral mention(s)	9 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Novo Nordisk A/S beats Novartis on 13 of the 21 factors compared between the two stocks.